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The generation of bradykinin in human plasma is initiated by the activation 
of Hageman factor (1-3). Activated Hageman factor and a  series of fragments 
derived  from  activated  Hageman  factor  by  digestion  with  the  fibrinolytic 
enzyme plasmin lead to the subsequent conversion of prekallikrein to kallikrein 
(4,  5). The smallest of the Hageman factor fragments is stable, has a tool wt of 
approximately  30,000-35,000,  and  appears  to  be  the  primary  activator  of 
prekallikrein  having  six  times  greater  prekallikrein-activating  activity  than 
the parent  Hageman factor molecule.  Cleavage of the substrate  kininogen by 
kallikrein  leads  to the  elaboration  of the  permeability  factor bradykinin  (6). 
In order to explore further the potential participation of the kinin-generating 
system in the inflammatory response,  certain of the various components were 
examined  for  chemotactic  activity.  The  generation  of  chemotactic  activity 
specific for human neutrophils  is  shown to result  from the  conversion of pre- 
kallikrein  to kallikrein.  Evidence is  also presented  that  both  the  chemotactic 
activity  and bradykinin-generating  activity  are  dependent  upon the integrity 
of the  active site  of kallikrein. 
Materials and Methods 
Bradykinin  triacetate  (Sandoz Pharmaceuticals,  Basel, Switzerland, or New England Nu- 
clear Corp., Cambridge, Mass.) was used as the standard  for native bradykinin.  Antisera to 
IgG, IgA, IgM,/~-lipoprotein,  transferrin, albumin, and whole human serum were purchased 
from Behring Diagnostics Inc., Woodbury, N. Y. Antiserum to human K and k Bence Jones 
proteins was obtained  from Melpar Inc., Falls Church, Va. Hexadimethrine  (polybrene) was 
a gift of Dr.  Floyd McIntire of Abbott Laboratories,  North  Chicago, 111. Plasma  throm- 
boplastin antecedent  (PTA)l-deficient  plasma containingless  than 1% of normal PTA activ- 
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ity was supplied by Dr. Anthony Britten (Boston, Mass.). Plasma thromboplastin component 
(PTC)-deficient plasma containing 2% normal PTC activity was obtained from Sera-Tec Bio- 
logicals,  New Brunswick, N. J. Diisopropyl fluorophosphate (DFP)  was a  product of Aldrich 
Chemical Co., Inc.,  Milwaukee,  Wis. Tosyl-L-lysine  chloromethyl ketone (TLCK)  was  ob- 
tained from Cyclo Chemical Division of Travenol Laboratory, Los Angeles, Calif. Ampholine 
earner ampholytes for use in isoelectric focusing were purchased from Microbiological Associ- 
ates Inc., Bethesda, Md. Ovalbumin 5X crystalized was a product of Pentex, Kankakee, Ill. 
Fractionation Procedures 
Serum was drawn for the isolation of active enzymes of the kinin-generating system and was 
processed as previously described (4). Diethylaminoethyl (DEAE)-cellulose chromatography, 
carboxymethyi  (CM)-cellulose chromatography,  Sephadex  G-100 gel filtration  (Pharmacia 
Fine Chemicals, Inc., Uppsala, Sweden), and disc gel electrophoresis at pH 9.3 were performed 
as previously described (4, 5). 
Plasma  was prepared for  the isolation of proenzymes of  the kinin-generating system as 
follows.  100 ml of blood were collected in plastic tubes containing 9 mg of disodium ethylene- 
diaminetetraacetate (EDTA) and 3.6 nag of hexadimethrine in 0.1 ml of 0.15 ~  saline for each 
10 ml of blood drawn. The tubes were immediately centrifuged at 930 g for 20 rain at 4°C and 
the plasma was separated using siliconized pipettes and dialyzed against 4 liters 0.01 ~t PO4 
buffer, pH 7.8. The dialysis bag was opened hourly, the plasma centrifuged at 900 g for 10 rain 
at 4°C to remove any precipitated protein, and the supernatant plasma dialyzed for a total of 
6 hr. Samples were concentrated by ultrafiltration using a UM-10 membrane (Amicon Corp., 
Lexington, Mass.) to 5-10 ml and then further concentrated by wall vacuum using Collodion 
bags No. 100 (Schliecher and Sehuell Inc., Keene, N. H.). 
Gel Filtralion.--A 2.5 )< 150 cm column of Sephadex G-150 superfine was equilibrated with 
0.02 M tris (hydroxymethyl) aminomethane (Tris) C1, pH 7.6. Samples of 2-3 ml were applied 
and the column run by upward flow at 5 ml/hr. 2.5-ml fractions were collected. 
A 5.0 3<  100 cm column of Sephadex G-200 was equilibrated with 0.01 ~  PO4 buffer, 0.15 M 
NaCI, pH 7.3. Samples of 4-5 ml were applied and the column run by upward flow at 10 ml/hr. 
5-ml fractions were collected. 
Qualernary Aminoethyl  (QAE)  Sephadex Chromatography.--A  5  >(  30 cm column of QAE 
Sephadex was equilibrated with 0.01 ~  1°O4 buffer, pH 7.8.30-ml samples dialyzed in 0.01 M 
PO.~ buffer, pH  7.8,  were applied  to  the column.  The column was  washed with 500 ml of 
equilibrating buffer and a linear salt gradient of 2 liters of equilibrating buffer and 2 liters of 
equilibrating buffer containing 0,3 M NaC1 was applied. The column was run at 60 ml/hr and 
12-mi fractions were c~llected. 
Sulfoethyl  (SE)  Sephadex  Chromatography.--A  5  >(  39 cm  column  of  SE  Sephadex  was 
equilibrated with 0.01 M 1OO4 buffer, pH  6.0.  30-ml samples dialyzed in 0.01 ~  PO4 buffer, 
pH 6.0, were applied. The column was washed with 500 ml of equilibrating buffer and a linear 
salt gradient of 2 liters of equilibrating buffer and 2 liters of equilibrating buffer containing 
0.5 M NaCI was applied. The columns were run at 60 ml/hr and 12-ml fractions were collected. 
Isoelectric Focusing in Gels.~Isoelectric  focusing in 4% polyacrylamide gels containing from 
pH 7 to 10 anapholytes was performed as described by Righetti and Drysdale (7). Samples of 
200/zl were each electrofocused in a series of gels; the ampholytes of one gel were removed by 
electrophoresis and the gel was stained with Coomassie blue in 20% ethanol and 7%  acetic 
acid. The others were cut in 5-ram slices and eluted in 0.2 ml of distilled water overnight at 
4°C. The pH of each slice was then measured and the eluates assayed. 
chemotactie factor of anaphylaxis;  PTA, plasma  thromboplastin antecedent; PTC,  plasma 
thromboplastin component; QAE,  quaternary aminoethyl; SE,  sulfoethyl; TLCK,  tosyl-L- 
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Preparation and  Assay  of  Components of  the  Bradykinin-Forming System.--Activated 
Hageman  factor  was  prepared  by  sequential  fracfionation  of plasma  on  QAE  Sephadex, 
Sephadex G-100,  CM-cellulose,and elution from disc gels after electrophoresis at pH 9.3  as 
previously described  (5,  8).  The prealbumin  Hageman factor fragments  were prepared  by 
sequential chromatography of serum on DEAE-cellulose, Sephadex G-100,  CM-cellulose, and 
elufion from disc gels after electrophoresis at pH 9.3 as previously described (5, 8). Preparation 
of prekallikrein and kallikrein are described in the Results section. 
Bradykinin was routinely determined by bioassay utilizing the isolated guinea pig ileum (9) 
or by radioimmunoassay  (10). Kallikrein, prekallikrein, and the prealbumin Hageman factor 
fragments were determined as previously described (4). Heat-inactivated plasma utilized as a 
source of the substrate kininogen was prepared as described by Jonasson and Becket (11). 
The shortening of the partial thromboplastin time of PTA-deficient plasma was used as an 
assay for PTA. Activated PTA was determined by incubating 0.05 ml of PTA source with 0.05 
ml cephalin reagent  (12) and 0.05 ml of PTA-deficient plasma for 2 rain at 37°C.  0.05 ml of 
0.05 M CaCl~. was added and  the clotting time determined at room  temperature. The  tubes 
were tilted each minute and the end point defined as the time interval required for the clot to 
adhere to the glass tube. Unactivated PTA was determined by incubation of 0.025 rnl of PTA 
source with 0.025 ml purified activated Hageman factor for 5 min at 37°C.  0.05 ml cephalin- 
kaolin reagent and 0.05 ml of PTA-deficient plasma were then added and the mixture further 
incubated at 37°C for 2 min. 0.05 ml 0.05 I~ CaC12 was added and the clotting time determined. 
Measurement of Chemotaxis.--Chemotaxis of human leukocytes was assayed by a modifica- 
tion of the Millipore technique of Boyden as previously described (13). Blood was drawn into 
plastic syringes and  transferred  to plastic tubes containing 50 units  of heparin/ml of blood. 
The red blood cells were allowed to settle for 90 min at 37°C, after which the leukocytes were 
removed and centrifuged for 5 rain at 100 g. The cells were washed once in Hanks' solution and 
resuspended  in Hanks'  solution containing 0.5%  ovalbumin at pH 7.3.  The cell count was 
adjusted to 1.5 ;K  106 leukocytes/ml. Chemotactic experiments were performed using a 3.0/~ 
pore size; except where stated otherwise, donors of peripheral blood leukocytes were normal 
volunteers. The 0.5% ovalbumin solution used as a  suspending medium in the chemotacfic 
chambers did not contain active kallikrein or a substrate for kallikrein. 
An anaphylactic  diffusate  from passively sensitized human  lung challenged with ragweed 
antigen  E  containing histamine,  slow  reacting  substance  of anaphylaxis  (SRS-A), and  an 
eosinophil chemotactic factor  of anaphylaxis  (ECF-A) was prepared  as  described  (14).  In 
experiments comparing the selective chemotacfic activity of kallikrein and ECF-A, Tyrode's 
solution in 0.5% ovalbumin was used as suspending medium both in the test and cell compart- 
ments.  Most preparations  of kallikrein were  dialyzed at  4°C  for  6-12  hr  against  Hanks' 
solution. Some kallikrein preparations, contained in Tris HC1 buffer, were assayed directly, the 
molarlty of the solution in the test compartment being adjusted to that of Hanks' solution. 
RESULTS 
Chemotactic  Activity  Associated  with  Plasma  Kallikrein.--Human  serum 
clotted  in  glass  so  as  to  activate Hageman  factor is known  to  possess  chemo- 
tactic  activity  (15,  16).  In  order  to  assess  whether  any  of  the  chemotactic 
activity  so  obtained  was  associated  with  the  appearance  of  serum  kalli- 
krein, 5 ml of human  serum were fractionated by Sephadex G-200 gel filtration 
as  shown in Fig.  1.  Three major peaks  of chemotactic  activity were observed, 
the first located between the IgM and IgG peaks, the second along the descend- 
ing  limb  of  the  IgG  peak,  and  the  third  with  low  molecular  weight  moieties 
eluting  subsequent  to  albumin.  Assay  of  the  column  for  kallikrein  activity 84  A  PREALBUMIN  ACTIVATOR  OF  PREKALLIKREIN.  III 
indicated  a  peak  which  was  superimposable  upon  the  second major  peak  of 
chemotactic  activity.  A  more  highly  purified  preparation  of  kallikrein  was 
therefore prepared in order to further assess  this association. 
Human serum was dialyzed against 0.01  5I PO4 buffer, pH 7.8,  and applied 
to  a  column of DEAE-cellulose. The effluent is known to  contain IgG  (17), 
kallikrein (18, 19), and activated PTA (20). Further fractionation by Sephadex 
G-150 gel filtration permitted partial separation of these three proteins and the 
fractions  so  obtained  were  assessed  for  chemotactic  activity  (Fig.  2).  The 
single peak of optical density at 280 m# represented primarily IgG as assessed 
by immunoelectrophoresis using  anti-whole human  serum.  The peak  of acti- 
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Fro.  1. Chromatography of human serum on Sephadex G-200. After a  preliminary assess- 
ment for kallikrein activity, the negative fractions were pooled into 100-ml lots, concentrated 
to  5  ml, and assayed for kinin-generating activity while the positive region extending from 
tubes No.  165  to  190 was divided into four portions, each concentrated to 5 ml and assayed 
for bradykinin-generating activity as indicated. Mean cell count refers to the average of the 
cell counts in five high power fields. 
vated PTA was found in the ascending limb of the IgG peak and had an esti- 
mated  tool  wt  of  170,000--175,000.  The  peak  of  kallikrein  activity  clearly 
followed the IgG peak and had an estimated mol wt of 130,000.  For chemo- 
tactic studies, the column fractions were pooled as follows: 1-40, 41-80, 81-120, 
121-150,  151-157,  158-190,  191-220,  221-245,  246-300  and  concentrated to 
10  ml  each  so  that  the  peak  of  activated  PTA would  be  essentially free of 
kallikrein. The chemotactic activity was found to overlap the peak of kallikrein 
activity. 
When the kallikrein-rich concentrate (Fig. 2) was assessed by disc gel electro- 
phoresis, the Coomassie blue stain revealed a single broad band in the y-globulin 
region (Fig. 3). An unstained gel was sliced in 2-mm sections, eluted in 0.5 ml 
of 0.15  ~  NaC1,  dialyzed against  Hanks'  solution,  and  assayed for kaltikrein 
activity and for chemotactic activity; both were located in the first two slices 
as shown in Fig. 3. In addition, some chemotactic activity was found in slice 7. ALLEN  P.  KAPLAN~ A.  B.  KAY,  AND  K.  FRANK  AUSTEN  85 
The majority of the cells which migrated in response to the various kallikrein 
preparations  in  the  experiments  described  above  were  neutrophils,  only an 
occasional eosinophil being noted. The  chemotactic activity of kallikrein for 
neutrophils was further investigated using peripheral blood leukocytes obtained 
from a patient who had an eosinophilia of 70% in association with seropositive 
rheumatoid arthritis. The chemotacfic response to kallikrein was  compared to 
that obtained with the anaphylactic diffusate containing ECF-A.  As shown in 
Fig. 4,  a  dose response was  obtained with each  chemotactic factor; however 
while  ECF-A  attracted  primarily  eosinophils,  the  kallikrein  preparation 
attracted only the patient's neutrophils. Bradykinin in concentrations of 1.0, 
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FIG. 2.  Sephadex G-150 superfine gel filtration of the DEAE-cellulose effluent  obtained 
with 0.01 ~ PO4 buffer,  pH 7.8. 
Chemotactic Activity  Resulting from  the Activation  of Prekallikrein.-- 
Preparation  and  Properties  of  Human  Prekallikrein.--30  ml  of  dialyzed 
plasma containing hexadimethrine were applied to a column of QAE Sephadex. 
The  effluent contained  IgG,  as  assessed  by  immunoelectrophoresis,  had  no 
detectable active kallikrein and had only trace  quantities of activated PTA. 
When 5 tzl of the effluent were incubated with 10/~1 of the purified Hageman 
factor  fragments  and  then  assayed for  bradykinin-generating activity  after 
incubation with 0.2 ml of heat-inactivated plasma, 100  ng of bradykinin were 
generated,  indicating  that  the  preparation  contained prekallikrein. Incuba- 
tion  of  25  ~1  of  the  QAE  Sephadex  effluent  with  25  tzl  of  activated 
Hageman factor shortened the partial  thromboplastin  time of PTA-deficient 
plasma  to  2.0  rain,  indicating  the  presence  of  unactivated  PTA  in  the 
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FIG 3.  Disc gel electrophoresis of the kallikrein-rich concentrate obtained from Sephadex 
G-IS0.  An unstained gel run simultaneously was sliced as indicated into  15  equal sections, 
eluted, and assayed for kallikrein and for chemotactic activity. 
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FIO. 4.  Comparative chemotaetic assay of kallikrein and ECF-A utilizing the peripheral 
blood leukocytes of a patient who had a  70% eosinophilla. ALLEN  P.  KAPLAN,  A.  B.  KAY~ AND  K.  FRANK  AUSTEN  87 
effluent. The addition of activated Hageman factor alone to the PTA-deficient 
plasma shortened the partial thromboplastin time from the control time of 28 
rain to 16 min. Addition of the effluent plus activated Hageman factor mixture 
in the same amounts as noted above to PTC-deficient plasma gave no shortening 
of the partial thromboplastin time. 
The QAE Sephadex effluent containing  IgG, prekallikrein, and unactivated 
PTA was then subjected to chromatography on SE Sephadex as shown in Fig. 5, 
resulting  in  separation  of prekallikrein from the  majority of IgG  and  from 
unactivated PTA. Prekallikrein eluted between 0.17  and 0.19 M NaC1 and was 
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FIG. 5. SE Sephadex  chromatography of the QAE Sephadex  effluent  obtained with 0.01 





activated by incubation with the Hageman factor fragments. The prekallikrein 
peak  was  then  pooled,  concentrated,  and  further  fractionated by  Sephadex 
G-150  gel  filtration  as  shown  in  Fig.  6.  When  the  prekallikrein  peak  was 
pooled and  concentrated,  neither unactivated  PTA  nor  activated  PTA was 
detectable. IgG, however, was still detectable by gel diffusion using anti-IgG or 
anti-n chain antisera. This preparation was then examined by disc gel electro- 
phoresis and isoelectric focusing in gels. Analysis of the preparation by disc gel 
electrophoresis revealed a faint broad band in the -r-globulin region. When an 
unstained disc  gel run sinmltaneously was  sliced in  2-mm slices,  eluted,  and 
assayed for prekallikrein, the activity was found only in the first two slices  at 
the  top  of  the  gel.  When  the  same  preparation  was  assessed  by isoelectric 88  A  PREALBUI~IIN  ACTIVATOR  OF  PREKALLIKREIN.  III 
focusing in polyacrylamide gels, a faint broad band was recognized extending 
from pH  7.5  to 8.9,  shown in  Fig.  7.  No  other discrete  bands  were visible. 
When an unstained gel run simultaneously was sliced,  eluted, and assayed for 
prekallikrein,  prekallikrein  was  found  between  slices  5  and  9,  which  cor- 
responded to an isoelectric point ranging from pH 8.5 to 8.9, the peak being at 
pH  8.7  (Fig.  7). 
Chemotactic A ctivity.--500 ~1 of the Hageman factor fragments were incubated 
with 250 #1 of prekallikrein obtained at the SE Sephadex step (Fig. 5) for 5 min 
at 37°C,  diluted to  1 ml with Hanks' solution, and dialyzed against Hanks' 
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FIG. 6. Sephadex G-150 gel filtration  of prekallikrein obtained  from SE Sephadex (Fig. 5). 
tivated plasma  generated 200  ng of bradykinin indicating conversion of the 
prekallikrein  to  kallikrein.  The  same  mixture  was  chemotactic  for  human 
neutrophils as shown in Table I, Experiment 1. Controls consisting of 250 #1 of 
prekallikrein incubated with 500 #1 of normal saline and 500 #1 of the Hageman 
factor fragments incubated with 250 ul of normal saline,  processed identically, 
did  not  generate  bradykinin from heat-inactivated plasma  and had  no  sig- 
nificant chemotactic activity.  Experiment  2  shows  a  similar result  utilizing 
prekallikrein obtained from the Sephadex G-150 gel filtration step (Fig. 6). 
Inhibition of Chemotactic Activity of Kallikrein.--The generation of bradykinin 
by human kallikrein is dependent upon an enzymatic site which is inhibitable 
by DFP (19, 21) through the action of this agent upon the hydroxyl group of a 
serine residue. The effect of DFP as well as an active site histidine inhibitor, 
TLCK, upon the chemotactic activity and the bradykinin-generating activity ALLEN  P.  KAPLAN~ A.  B.  KAY~ AND  K.  FRANK  AUSTEN  89 
of kallikrein  was examined.  300/~1 of kallikrein were made 10  -3 ~  in DFP or 
10  -3 M in TLCK, the mixture incubated for 15 rain at 37°C  and dialyzed three 
times  against 500 ml of Hanks' solution for 12 hr.  700 #1 of Hanks' solution 
were then added to each sample and the samples assayed for chemotactic and 
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FIG. 7. Isoelectric focusing in 4% polyacrylamide gels of the prekallikrein-rich concen- 
trate obtained  from Sephadex G-150 gel filtration (Fig. 6). An unstained gel run simultaneously 
was sliced into 21 equal sections of 5 mm each and assayed for pH and prekallikrein. 
were each added to 100/~1 of 0.02  ~  Tris CI, pH  7.6, the buffer in which the 
kallikrein  preparation was stored,  and dialyzed three times against 500 ml of 
Hanks' solution for 12 hr. 300 ~ul of kallikrein were then added, incubated for 
15 rain  at 37°C,  the volume brought to  1.0 ml with Hanks' solution,  and as- 
sayed for chemotactic and kinin-generating activity. As shown in Fig. 8, DFP 
treatment  of  kallikrein  abolished  both  kinin-generating  and  chemotactic 
activity  (B),  while  removal  of DFP  from  the  buffer  by  dialysis  before  the 
introduction of kallikrein had no effect upon these two functions (D). No effect 
was seen with 10  -3 ~  TLCK (C). 90  A  PREALBUMIN  ACTIVATOR OF  PREKALLIKREIN.  III 
A  dose  response  experiment  for  inhibition  of  chemotaxis  and  bradykinin 
generation by TLCK and DFP is  shown in  Fig.  9.  The experiment was per- 
formed as described above except the incubation time of kallikrein  with each 
TABLE  I 
Generation  of  Chemotactic Activity for  Human  Neutrophils  by  Activation  of Prekallikrein 
Hageman  Prekallikrein  jr 
Prekallik rein  factor  Hageman  factor 
fragments  fragments 
Experiment 1" 
Neutrophil chemotaxis  0  1.5  14.2 
(mean cell count) 
Bradykinin generated from  0  0  200 
heat-inactivated plasma (ng) 
Experiment 2~: 
Neutrophil chemotaxis  0  0  15 
(mean cell count) 
Bradykinin generated from  0  0  175 
heat-inactivated plasma (ng) 
* Prekallikrein obtained from SE Sephadex step. 
:~ Prekallikrein obtained from Sephadex G-150 step. 
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FIG. 8.  Effect of lO--3M DFP and 1O-a•  TLCK upon the chemotactic and bradykinin- 
generating activity of kallikrein. (A)  Kallikrein control. (B)  Kallikrein made 10  -a M in DFP. 
(C)  Kallikrein made 10  -a ~  in TLCK.  (D)  Kallikrein added to dialyzed DFP solution.  (E) 
KaUikrein added to dialyzed TLCK solution. 
inhibitor was 30 rain.  Longer incubation at  this temperature  resulted in non- 
specific  loss  of both  kallikrein  functions.  No  inhibition  of  either  activity  is 
obtained  with  TLCK until  a  10  --2 M concentration is  used.  A  dose  response 
inhibition of both activities was  obtained with  DFP  between 0.25  X  10  -a  ~ 
and 1.0 X  10  -a ~. ALLEN  P.  KAPLAN~  A.  B.  KAY,  AND  K.  FRANK  AUSTEN  91 
In order to determine whether the inhibition of DFP is related to the active 
site  of kallikrein,  an  experiment was performed in which the  action  of DFP 
upon prekallikrein and kallikrein was compared. 1 Inl of prekallikrein obtained 
from plasma by QAE Sephadex, SE Sephadex, and Sephadex G-150 chromatog- 
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FIG. 9.  Dose response inhibition of both chemotactic  and bradyklnin-generatlng activity of 
kallikrein utilizing TLCK and DFP. 
raphy was incubated with 100 M1 of Hagelnan factor fragments for 20 rain at 
37°C.  The mixture was then divided in half,  one portion was made  10  -3 ~  in 
DFP  and both were  further  incubated  at  37°C  for  15 Inin,  brought to  1 ml 
volume  with  Hanks'  solution,  and  dialyzed  three  times  against  500  ml  of 
Hanks' solution for 12 hr. Two 500 #l aliquots of prekallikrein were first made 
10  -3 M in DFP, incubated at 37°C for 15 Inin, and dialyzed three times against 92  A  PREALBUMIN  ACTIVATOR  OF  PREKALLIKREIN.  III 
500 ml of Hanks' solution for 12 hr. One portion was then activated by addition 
of 50 ~1 of the Hageman factor fragments, the mixture incubated for 20 rain at 
37°C,  and both aliquots were then brought to 1 ml volume with Hanks' solu- 
tion.  Controls  consisting  of  prekallikrein  or  the  Hageman  factor  fragments 
alone,  each brought  to  the  same  final  concentrations  utilized  above  by  the 
addition of normal saline, were subjected to each incubation and dialysis step. 
Each preparation was then assayed for bradykinin-generating and  chemotactic 
activity. As shown in Fig.  10,  the prekallikrein preparation (A), the Hageman 
factor fragments (B), and the mixture of prekallikrein and the Hageman factor 
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Fro. 10.  Comparison of the effect of DFP upon kallikrein and prekallikrein. (A) Prekal- 
likrein preparation.  (B)  Hageman factor  fragments.  (C)  Prekallikrein activated  with  the 
Hageman factor fragments. (D) Prekallikrein activated with the Hageman factor fragments 
and made 10  -~ ~ in DFP.  (E) Prekallikrein made 10  .3 ~ in DFP,  dialyzed, then activated 
with the Hageman factor fragments. 
from heat-inactivated plasma and possessed no chemotactic activity. Exposure 
of  prekallikrein  alone  to  10  .3  5I  DFP  generated  no  bradykinin  from  heat- 
inactivated  plasma  and  possessed no  chemotactic  activity.  Exposure  of pre- 
kallikrein  to  10  -3 ~l  DFP  followed  by dialysis to  remove the  DFP  and  sub- 
sequent  conversion  to  kallikrein  by  incubation  with  the  Hageman  factor 
fragments  (E)  revealed 80%  of the kinin-generating activity and 50% of the 
chemotactic  activity  of  prekallikrein  which  was  activated  without  prior 
exposure  to  DFP  (C). 
DISCUSSION 
When  human blood is clotted in glass,  thereby activating Hageman factor, 
the serum obtained has been shown to possess chemotactic activity (15). This 
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of Hageman factor not only initiates the intrinsic  pathway of blood coagulation 
(22, 23) and the fibrinolytic system (24, 25) but also the kinin-forming  sequence, 
it seemed appropriate to evaluate the components of the kinin-forming  system 
as possible contributors to the chemotactic activity of normal serum. Fractiona- 
tion of normal senml on Sephadex  G-200 revealed several peaks of chemotactic 
activity of which one coincided  with the peak of kallikrein  (Fig.  1), the most 
heat-labile component of the kinin-forming  system (26). 
The evidence that kallikrein  is chemotactic for human neutrophils includes 
the superposition of kinin-generating  and chemotactic activity when partially 
purified  kallikrein  is  further  fractionated  by  Sephadex  G-150  gel  filtration 
(Fig.  2) and by electrophoresis  in alkaline  disc gels (Fig.  3). Further evidence 
that chemotactic activity is a function of active kallikrein  is provided by the 
finding  that  conversion  of prekallikrein  to kallikrein  by the Hageman  factor 
fragments is associated with the appearance of chemotactic activity whereas 
neither prekallikrein  nor the Hageman factor fragments alone exhibited such a 
property (Figs. 5, 6, Table I). Although it seemed possible that the chemotactic 
activity observed might be due to a small fragment formed during conversion 
of  prekallikrein  to  kallikrein,  attempts  to  dissociate  such  a  fragment  from 
kallikrein  by rechromatography on G-75 at pH 3.5 failed to reveal chemotactic 
activity  except  in  association  with  the  kallikrein  peak.  Furthermore,  the 
capacity of DFP to inhibit both chemotaxis and kinin generation  (Figs. 8, 9) 
is  consistent  with  chemotaxis  being  an  intrinsic  function  of  the  kallikrein 
molecule itself. 
Lewis has shown that intradermal injections of relatively high concentrations 
of bradykinin (1-100 #g/ml) in the rabbit promotes the migration of leukocytes 
(27).  Of the components of the kinin-forming  system thus far examined,  the 
Hageman  factor  fragments,  prekallikrein,  kallikrein,  and  bradykinin,  only 
kallikrein  was chemotactic. Furthermore,  kallikrein  attracted neutrophils but 
not eosinophils from a mixed leukocyte population, even when the suspension 
contained  70%  eosinophils  (Fig.  4).  In  contrast,  an  eosinophil  chemotactic 
factor  released  from  human  lung  sensitized  with  IgE  and  challenged  with 
specific  antigen  attracted  eosinophils  but  not  neutrophils  under  the  same 
experimental  conditions  (14)  (Fig.  4). 
The activation of Hageman factor by a variety of biologic materials such as 
collagen  (28, 29),  sodium urate crystals (30), pyrophosphate crystals (30), L- 
homocystine crystals (31), and human articular cartilage (32), and the capacity 
of  activated  Hageman  factor  to  convert  prekallikrein  to  kallikrein  either 
directly  or  through  its  prealbumin  fragments  (5)  offers  a  nonimmunologic, 
readily activatable mechanism for the generation  of  a  chemotactic principle 
independent of the complement system. It is noteworthy that kallikrein  is not 
only chemotactic for human neutrophils but also leads to the generation of the 
permeability factor bradykinin; two other chemotactic factors, fragments from 
the third and fifth components of complement both promote leukocyte migra- 94  A  PREALBUMIN  ACTIVATOR  OF  PREKALLIKREIN.  III 
tion in vitro (33, 34) and also increase vascular permeability by virtue of their 
anaphylatoxic activity (35,  36).  It may be that  a  change in vascular perme- 
ability plays a role in determining whether or not a chemotactic principle can 
express this capability in an in vivo situation. 
A  series of esterases present in rabbit neutrophils, which play an essential 
role in the chemotactic response, have been described (37-39). That the active 
site of kallikrein is required for the expression of its chemotactic activity could 
be explicable either by direct activation of one of these esterases or through a 
substitution  which  bypasses  an  activation  step  utilized  by  nonenzymatic 
chemotactic factors. The relatively high concentration of DFP utilized in the 
inhibition  experiments  was  necessitated  by  the  requirement  to  inactivate 
kallikrein at 37°C within a 15 rain period; incubation of kallikrein beyond this 
interval was  associated  with  a  loss  in  activity which  reached  100%  in  2 hr. 
The histidine inhibitor TLCK, however, was inactive at the same concentra- 
tion and  conditions  (Fig. 9). The findings that the precursor form of the  en- 
zyrne,  prekaUikrein,  tolerated  a  dose  of DFP  which  completely inactivated 
kallikrein (Fig. 10) is consistent with studies of other serine esterases in which 
the  precursor enzyme was  resistant  to inactivation  (40,  41).  Since both  the 
Hageman factor fragments and kallikrein are sensitive to inactivation by DFP 
(19,  21, 42), the partial loss of activity experienced by the prekallikrein could 
be  attributed  to residual DFP  despite the  extensive dialysis. 
SISMMAR¥ 
Human plasma kallikrein has been shown to directly  and selectively  attract 
human neutrophils from a mixed leukocyte  population. The capacity  of plasma 
kallikrein to  be  chemotactic and  to  generate the  nonapeptide bradykinin 
was maintained  during progressive purification. While neither highly purified 
prekallikrein nor the prealbumin Hageman factor fragments  were chemotactic 
alone, their interaction  so as to convert  preka]likreln to kallikrein  yielded  both 
chemotactic and kinin-generating activity. Both functions  of kallikrein were 
inhibited by treatment with diisopropyl fluorophosphate, indicating an  es- 
sential role/or the active  site of the enzyme  in the expression of its chemotactic 
activity. 
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